Our studies not only demonstrate that targeting TLR2 generates metastases clearing immunity, but also reveals a signal transduction pathway in the tumor by which HSP60 liberated from B16 cells, causes a persistent activation of TLR2 to maintain the constitutive activity and function of Stat3 in these cells and determine the development of tumor immune tolerance. This evidence concerns the gene TLR2 and neoplasm.